Eli Lilly and Company

Mitchell I Steinberg

Jon Kevin Reel

Winston S Marshall

Richard L Simon

Celia A Whitesitt

Sherryl L Lifer

Bryan B Molloy

Alan David Palkowitz

William Pfeifer

K Jeff Thrasher

Donald B Boyd

Fariborz Mohamadi

Gary A Koppel

Bruce Anthony Dressman

Stephen W Kaldor

John Robert Rizzo

Robert F Bruns, Jr

David C Hunden

Venkatraghavan Vasudevan

Jeffrey J Skelton

Kumiko Takeuchi

Timothy A Grese

Prabhakar Kondaji Jadhav

Kenneth Lee Hauser

Robin D G Cooper

Donald Paul Matthews

David W Robertson

Robin D Cooper

Michael Gregory Bell

David Andrew Neel

Donald R Gehlert

Kurt Rasmussen

Peter Ambrose Lander

Mary Jeanne Kallman

Jonathan Edward Green

Thomas F Bumol

Kevin Robert Fales

Michael Joseph Coghlan

Donald R Holland

August Masaru Watanabe

Venkatraghaven Vasudevan

Matthew Lee Brown

Sally Ann Wiest

The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula I, including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula I.

Tricyclic steroid hormone nuclear receptor modulators

The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation, particularly congestive heart failure, comprising administering to a patient in need thereof an effective amount of a compound of the formula: I or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula I, including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula I 

Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators

Non-peptidyl vasopressin V1A antagonists

Non-peptidyl vasopressin V1a antagonists

This invention provides methods and 2-(azetidin-2-on-1-yl)acetic acid derivatives for the antagonism of the vasopressin V,receptor.

The present invention relates to a process for discovering compounds that modulate novel I.sub.2 binding sites (e.g. BFI binding sites) in human tissue, as well as a process for identifying TCP-like compounds that potentiate BFI binding.

Potentiation of �.sup.3 H! 2-(2-benzofuranyl)-2-imidazoline (BFI)

This invention provides methods of inhibiting pulmonary hypertensive disease which comprise administering to a mammal in need thereof a compound having activity as a tachykinin receptor antagonist.

Methods of treating pulmonary hypertension

This invention provides a method for treating a condition resulting from the cessation or withdrawal of tobacco or nicotine, opioids, ethanol or combinations thereof comprising administering an effective amount of 4-chloro-5-(imidazoline-2-y(amino)-6-methoxy-2-methylpyrimidine.

Method for treating substance abuse withdrawal

This invention provides novel heterocyclic derivatives, their pharmaceutical formulations, and their use for antagonizing angiotensin II receptors in mammals.

Angiotensin II antagonists

This invention provides novel phenyl and heterocyclic derivatives, their pharmaceutical formulations and their use for antagonizing angiotensin II receptors in mammals.

Angiotensin II antagonist intermediates

This invention provides novel phenyl and heterocyclic derivatives, their pharmaceutical formulations and their methods of use for antagonizing angiotensin II receptors in mammals.

Growing community of inventors

Indianapolis, IN, United States of America

Mitchell I Steinberg